Study on the use of Panax NotoGinseng LUOTAI in ischemic stroke in Senegal
Phase 4
- Conditions
- Circulatory SystemCardiology
- Registration Number
- PACTR201907715482365
- Lead Sponsor
- KPC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- All
- Target Recruitment
- 152
Inclusion Criteria
Ischemic stroke less than 7 days
Exclusion Criteria
•Age inf 40 YO or sup 70YO
•Stroke in the 3 last year
•Refuse study
•No possibility oral médication
•Brain trauma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of Panax NotoGinseng LUOTAI in ischemic stroke treatment?
How does Panax NotoGinseng LUOTAI compare to standard-of-care treatments for ischemic cerebrovascular accidents in Senegal?
Are there specific biomarkers that indicate patient suitability for Panax NotoGinseng LUOTAI therapy in ischemic stroke?
What are the potential adverse events associated with Panax NotoGinseng LUOTAI in phase IV trials for cerebrovascular accidents?
What other compounds or combination therapies are being explored alongside Panax NotoGinseng LUOTAI for ischemic stroke management?